Endo's Fortesta To Join Crowded Testosterone Treatment Market In Q1
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA approved the testosterone gel despite concerns about secondary exposure, but Fortesta will be competing against entrenched rivals and a new treatment from Eli Lilly.
You may also be interested in...
Third Time’s A Charm? Endo’s Injectable Testosterone Finally Ready For Advisory Cmte.
FDA says reports of oil embolism and anaphylactic reations with other testosterone injectables also will be part of the discussion during an April 18 meeting of the Reproductive Health Drugs and Drug Safety and Risk Management advisory committees to review Aveed (testosterone undecanoate).
Endo Launches Fortesta, Raises 2011 Guidance
Three years after a new management team stepped in at Endo Pharmaceuticals, the specialtypharma appears to be using M&A to diversify successfully beyond its core pain franchise.
Endo Launches Fortesta, Raises 2011 Guidance
Three years after a new management team stepped in at Endo Pharmaceuticals, the specialtypharma appears to be using M&A to diversify successfully beyond its core pain franchise.